GlassScriptPhysician profile
Matthew N Klain
NPI 1952367401
$3,570.30
in general payments reported to CMS, 2019-2025
34 companies · $900 in 2025
The $900 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $101 · 2021: $270 · 2022: $223 · 2023: $449 · 2024: $905 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,252 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,252.43 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $633.40 | 2021-2025 | |
| Lilly USA, LLC | $422.40 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $318.19 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $264.21 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $226.02 | 2019-2025 | |
| Novo Nordisk INC | $216.54 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $175.95 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.86 | 2019-2025 | Jardiance |
| Abbott Laboratories | $154.92 | 2022-2025 | Proclaim, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $153.09 | 2019-2024 | Farxiga, Airsupra |
| Phathom Pharmaceuticals, INC. | $107.34 | 2024-2025 | Voquezna |
| Amgen INC. | $73.12 | 2019-2020 | |
| Exact Sciences Corporation | $67.74 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $67.50 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $62.72 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $58.42 | 2019-2024 | Eliquis |
| Dexcom, INC. | $39.78 | 2024-2025 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $35.36 | 2024-2025 | Vowst |
| Takeda Pharmaceuticals U.S.A., INC. | $34.77 | 2025 | Glassia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.11 | 2025 | Caplyta |
| Currax Pharmaceuticals LLC | $29.57 | 2025 | Contrave, Onzetra Xsail |
| Daiichi Sankyo INC. | $28.45 | 2023 | Injectafer |
| Sanofi-Aventis U.S. LLC | $26.94 | 2025 | |
| Ardelyx, INC. | $25.83 | 2025 | Ibsrela |
| Boston Scientific Corporation | $19.46 | 2024 | Watchman |
| Biohaven Pharmaceutical Holding Company LTD. | $18.46 | 2022 | |
| Sumitomo Pharma America, INC. | $18.00 | 2023-2025 | Gemtesa |
| Insulet Corporation | $17.77 | 2023 | Omnipod |
| Lundbeck LLC | $16.18 | 2023 | Rexulti |
| Vertical Pharmaceuticals, LLC | $16.16 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.23 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.02 | 2021 | |
| Allergan, INC. | $12.87 | 2019 | |
| Paratek Pharmaceuticals, INC. | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Klain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.